264 related articles for article (PubMed ID: 9804773)
1. Defective release of corepressor by hinge mutants of the thyroid hormone receptor found in patients with resistance to thyroid hormone.
Safer JD; Cohen RN; Hollenberg AN; Wondisford FE
J Biol Chem; 1998 Nov; 273(46):30175-82. PubMed ID: 9804773
[TBL] [Abstract][Full Text] [Related]
2. A novel natural mutation in the thyroid hormone receptor defines a dual functional domain that exchanges nuclear receptor corepressors and coactivators.
Tagami T; Gu WX; Peairs PT; West BL; Jameson JL
Mol Endocrinol; 1998 Dec; 12(12):1888-902. PubMed ID: 9849963
[TBL] [Abstract][Full Text] [Related]
3. Lack of coactivator interaction can be a mechanism for dominant negative activity by mutant thyroid hormone receptors.
Liu Y; Takeshita A; Misiti S; Chin WW; Yen PM
Endocrinology; 1998 Oct; 139(10):4197-204. PubMed ID: 9751500
[TBL] [Abstract][Full Text] [Related]
4. Very strong correlation between dominant negative activities of mutant thyroid hormone receptors and their binding avidity for corepressor SMRT.
Matsushita A; Misawa H; Andoh S; Natsume H; Nishiyama K; Sasaki S; Nakamura H
J Endocrinol; 2000 Dec; 167(3):493-503. PubMed ID: 11115777
[TBL] [Abstract][Full Text] [Related]
5. Pathological Interactions Between Mutant Thyroid Hormone Receptors and Corepressors and Their Modulation by a Thyroid Hormone Analogue with Therapeutic Potential.
Harrus D; Déméné H; Vasquez E; Boulahtouf A; Germain P; Figueira AC; Privalsky ML; Bourguet W; le Maire A
Thyroid; 2018 Dec; 28(12):1708-1722. PubMed ID: 30235988
[TBL] [Abstract][Full Text] [Related]
6. Resistance to thyroid hormone caused by two mutant thyroid hormone receptors beta, R243Q and R243W, with marked impairment of function that cannot be explained by altered in vitro 3,5,3'-triiodothyroinine binding affinity.
Yagi H; Pohlenz J; Hayashi Y; Sakurai A; Refetoff S
J Clin Endocrinol Metab; 1997 May; 82(5):1608-14. PubMed ID: 9141558
[TBL] [Abstract][Full Text] [Related]
7. Aberrant dynamics of histone deacetylation at the thyrotropin-releasing hormone gene in resistance to thyroid hormone.
Ishii S; Yamada M; Satoh T; Monden T; Hashimoto K; Shibusawa N; Onigata K; Morikawa A; Mori M
Mol Endocrinol; 2004 Jul; 18(7):1708-20. PubMed ID: 15131262
[TBL] [Abstract][Full Text] [Related]
8. Thyroid hormone resistance syndrome manifests as an aberrant interaction between mutant T3 receptors and transcriptional corepressors.
Yoh SM; Chatterjee VK; Privalsky ML
Mol Endocrinol; 1997 Apr; 11(4):470-80. PubMed ID: 9092799
[TBL] [Abstract][Full Text] [Related]
9. A novel TR beta mutation (R383H) in resistance to thyroid hormone syndrome predominantly impairs corepressor release and negative transcriptional regulation.
Clifton-Bligh RJ; de Zegher F; Wagner RL; Collingwood TN; Francois I; Van Helvoirt M; Fletterick RJ; Chatterjee VK
Mol Endocrinol; 1998 May; 12(5):609-21. PubMed ID: 9605924
[TBL] [Abstract][Full Text] [Related]
10. N-terminal variants of thyroid hormone receptor beta: differential function and potential contribution to syndrome of resistance to thyroid hormone.
Ng L; Forrest D; Haugen BR; Wood WM; Curran T
Mol Endocrinol; 1995 Sep; 9(9):1202-13. PubMed ID: 7491112
[TBL] [Abstract][Full Text] [Related]
11. Determination of nuclear receptor corepressor interactions with the thyroid hormone receptor.
Makowski A; Brzostek S; Cohen RN; Hollenberg AN
Mol Endocrinol; 2003 Feb; 17(2):273-86. PubMed ID: 12554754
[TBL] [Abstract][Full Text] [Related]
12. A novel thyroid hormone receptor-beta mutation that fails to bind nuclear receptor corepressor in a patient as an apparent cause of severe, predominantly pituitary resistance to thyroid hormone.
Wu SY; Cohen RN; Simsek E; Senses DA; Yar NE; Grasberger H; Noel J; Refetoff S; Weiss RE
J Clin Endocrinol Metab; 2006 May; 91(5):1887-95. PubMed ID: 16464943
[TBL] [Abstract][Full Text] [Related]
13. Two separate NCoR (nuclear receptor corepressor) interaction domains mediate corepressor action on thyroid hormone response elements.
Cohen RN; Wondisford FE; Hollenberg AN
Mol Endocrinol; 1998 Oct; 12(10):1567-81. PubMed ID: 9773980
[TBL] [Abstract][Full Text] [Related]
14. Quantification of ligand-regulated nuclear receptor corepressor and coactivator binding, key interactions determining ligand potency and efficacy for the thyroid hormone receptor.
Jeyakumar M; Webb P; Baxter JD; Scanlan TS; Katzenellenbogen JA
Biochemistry; 2008 Jul; 47(28):7465-76. PubMed ID: 18558711
[TBL] [Abstract][Full Text] [Related]
15. Requirement of corepressor binding of thyroid hormone receptor mutants for dominant negative inhibition.
Nagaya T; Fujieda M; Seo H
Biochem Biophys Res Commun; 1998 Jun; 247(3):620-3. PubMed ID: 9647743
[TBL] [Abstract][Full Text] [Related]
16. Nuclear corepressors enhance the dominant negative activity of mutant receptors that cause resistance to thyroid hormone.
Tagami T; Jameson JL
Endocrinology; 1998 Feb; 139(2):640-50. PubMed ID: 9449636
[TBL] [Abstract][Full Text] [Related]
17. The interaction of the vitamin D receptor with nuclear receptor corepressors and coactivators.
Tagami T; Lutz WH; Kumar R; Jameson JL
Biochem Biophys Res Commun; 1998 Dec; 253(2):358-63. PubMed ID: 9878542
[TBL] [Abstract][Full Text] [Related]
18. A novel mechanism of thyroid hormone-dependent negative regulation by thyroid hormone receptor, nuclear receptor corepressor (NCoR), and GAGA-binding factor on the rat cD44 promoter.
Kim SW; Ho SC; Hong SJ; Kim KM; So EC; Christoffolete M; Harney JW
J Biol Chem; 2005 Apr; 280(15):14545-55. PubMed ID: 15701601
[TBL] [Abstract][Full Text] [Related]
19. The nuclear corepressors recognize distinct nuclear receptor complexes.
Cohen RN; Putney A; Wondisford FE; Hollenberg AN
Mol Endocrinol; 2000 Jun; 14(6):900-14. PubMed ID: 10847591
[TBL] [Abstract][Full Text] [Related]
20. Thyroid hormone receptor-beta mutants associated with generalized resistance to thyroid hormone show defects in their ligand-sensitive repression function.
Piedrafita FJ; Ortiz MA; Pfahl M
Mol Endocrinol; 1995 Nov; 9(11):1533-48. PubMed ID: 8584031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
